DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

東京ビッグサイト

2017年11月12日 (日) 午前 9:30 - 2017年11月14日 (火) 午後 5:30

〒135-0063, 東京都江東区有明3-11-1

第14回DIA日本年会

[V6-S2] Paradigm Shift in Global Development Strategy - How to Utilize ICH E17 GL in New Drug Development? -

Session Chair(s)

Manabu  Yanagisawa, PHD

Manabu Yanagisawa, PHD

Director, Global Scientific and Regulatory Affairs, Japan Pharmaceutical Manufacturers Association, Japan

The ICH E17 guideline is expected to reach Step 4 in 4Q 2017. This session will provide an opportunity to discuss how to utilize E17 appropriately, where global development strategy move toward, and what can be done to induce a change in our strategy. We have experienced so many evaluations of consistent or similar results among ethnic groups under E5 guideline and we know how difficult evaluation of ethnic differences and consistency among ethnic groups are. Given those experiences, this session will also address the points to consider in planning a global development program by means of E17, newly introduced pooling strategies (pooled region, pooled subpopulation), what kind of information is need for pooling, when such information to be obtained, how to present results from the Multi-Regional Clinical Trials. Those discussions would contribute to your readiness for the paradigm shift in global development strategy.

Speaker(s)

Nobushige  Matsuoka, PHD

Nobushige Matsuoka, PHD

Group Lead, Clinical Statistics Group 2, Biometrics & Data Management, Pfizer R&D Japan G.K., Japan

How should be the Future of Simultaneous Global Drug Development? - Road to Implementation of ICH E17 -

Masahiro  Tohkin, PHD

Masahiro Tohkin, PHD

Professor, Nagoya City University, Japan

Ethnic Differences on Efficacy and Safety in a Multi-Regional Clinical Trial

Koichi  Miyazaki, PHD

Koichi Miyazaki, PHD

Senior Director, Group IV, Oncology Clinical Development Department, Daiichi Sankyo Co., Ltd., Japan

The Impact of ICH-E17 on Clinical Development Strategy and Operations

Osamu  Komiyama

Osamu Komiyama

CEO, Office Komiyama, Japan

Yoshiaki  Uyama, PHD, MS, RPH

Yoshiaki Uyama, PHD, MS, RPH

Associate Executive Director, Regulatory Science Center, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Hiroshi  Takeda, PHD, MS

Hiroshi Takeda, PHD, MS

Technical Officer, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。